Trial | Agent | PARPi duration | MDS/AML events by arm/total # of patients | % patients with MDS/AML in PARPi versus comparator arm | |
PARPi | Comparator | ||||
SOLO1[1] | Olaparib | 2 years | 4/260 | 1/130 | 1.5 versus <1 |
PRIMA 2024[2] | 11/484 | 4/244 | 2.3 versus 1.6 | ||
PAOLA1[3] | Olaparib | 2 years | 6/535 | 1/267 | 1 versus <1 |
Study19[4] | Olaparib | Until disease progression, 18% >3 years | 2/136 | 1/129 | 1.5 versus <1 |
SOLO2[5] | Olaparib | Until disease progression, mean 29.1 months | 16/195 | 4/99 | 8 versus 4 |
NOVA[6] | Niraparib | Until disease progression | 13/367 | 3/179 | 3.5 versus 1.7 |
| 9/136 | 2/65 | 6.6 versus 3.1 | ||
| 4/231 | 1/114 | 1.7 versus 0.9 | ||
ARIEL3[7] | Rucaparib | Until disease progression, median 8.3 months | 14/372 | 6/189 | 3.8 versus 3.2 |
| 9/79 (11.4%) | ||||
| 5/245 | 1/123 | 2 versus 0.8 | ||
| 9/130 | 3/63 | 6.9 versus 4.8 | ||
| 7/46 (15.2%) |